Annika Allqvist1, Jun Miura, Leif Bertilsson, Rajaa A Mirghani. 1. Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Pharmacology at Karolinska University Hospital, Huddinge, Stockholm, Sweden. annika.allqvist@ki.se
Abstract
OBJECTIVE: The antifungal drug ketoconazole (KTZ) is known as an inhibitor of, especially, the CYP3A subfamily, which catalyzes the metabolism of a large variety of drugs. Interactions between KTZ and CYP3A substrates have been reported both in vivo and in vitro. Most of them, however, involved the KTZ racemate. KTZ racemate and the separate enantiomers, 2R,4R; 2R,4S; 2S,4S, and 2S,4R, were evaluated for their selectivity in inhibiting alprazolam and quinine metabolism. METHODS: The inhibition of alprazolam and quinine metabolism was studied in an in vitro system of human liver microsomes (HLM), recombinant of CYP3A4 and CYP3A5. The concentrations of formed 3-hydroxyquinine and 4- and alpha-hydroxyalprazolam were measured by HPLC and LC-MS, respectively. RESULTS: Quinine 3-hydroxylation was catalyzed to a similar extent by CYP3A4 and CYP3A5. The formation rate of 4-hydroxyalprazolam was higher than that of alpha-hydroxyalprazolam for each HLM, CYP3A4 and CYP3A5. KTZ racemate and enantiomers showed differential inhibitory effects of quinine and alprazolam metabolism. Quinine metabolism catalyzed by HLM, CYP3A4 and CYP3A5 was potently inhibited by the trans-enantiomer KTZ 2S,4S, with IC(50) value of 0.16 microM for HLM, 0.04 microM for CYP3A4 and 0.11 microM for CYP3A5. The same enantiomer showed the lowest IC(50) values of 0.11 microM for HLM and 0.04 microM for CYP3A5 with respect to alprazoalm 4-hydroxylation and also the same pattern for alprazolamalpha-hydroxylation, 0.13 microM for HLM and 0.05 microM for CYP3A5. Alprazolam metabolism (both alpha- and 4- hydroxylations) catalyzed by CYP3A4 was inhibited potently by the cis-enantiomer KTZ 2S,4R, with IC(50) values of 0.03 microM. CONCLUSIONS: Alprazolam and quinine metabolism is catalyzed by both CYP3A4 and CYP3A5. The present study showed that different KTZ enantiomers inhibit CYP3A4 and CYP3A5 to different degrees, indicating that structural differences among the enantiomers would be related to their inhibitory potency on these two enzymes.
OBJECTIVE: The antifungal drug ketoconazole (KTZ) is known as an inhibitor of, especially, the CYP3A subfamily, which catalyzes the metabolism of a large variety of drugs. Interactions between KTZ and CYP3A substrates have been reported both in vivo and in vitro. Most of them, however, involved the KTZ racemate. KTZ racemate and the separate enantiomers, 2R,4R; 2R,4S; 2S,4S, and 2S,4R, were evaluated for their selectivity in inhibiting alprazolam and quinine metabolism. METHODS: The inhibition of alprazolam and quinine metabolism was studied in an in vitro system of human liver microsomes (HLM), recombinant of CYP3A4 and CYP3A5. The concentrations of formed 3-hydroxyquinine and 4- and alpha-hydroxyalprazolam were measured by HPLC and LC-MS, respectively. RESULTS:Quinine 3-hydroxylation was catalyzed to a similar extent by CYP3A4 and CYP3A5. The formation rate of 4-hydroxyalprazolam was higher than that of alpha-hydroxyalprazolam for each HLM, CYP3A4 and CYP3A5. KTZ racemate and enantiomers showed differential inhibitory effects of quinine and alprazolam metabolism. Quinine metabolism catalyzed by HLM, CYP3A4 and CYP3A5 was potently inhibited by the trans-enantiomer KTZ2S,4S, with IC(50) value of 0.16 microM for HLM, 0.04 microM for CYP3A4 and 0.11 microM for CYP3A5. The same enantiomer showed the lowest IC(50) values of 0.11 microM for HLM and 0.04 microM for CYP3A5 with respect to alprazoalm 4-hydroxylation and also the same pattern for alprazolamalpha-hydroxylation, 0.13 microM for HLM and 0.05 microM for CYP3A5. Alprazolam metabolism (both alpha- and 4- hydroxylations) catalyzed by CYP3A4 was inhibited potently by the cis-enantiomer KTZ2S,4R, with IC(50) values of 0.03 microM. CONCLUSIONS:Alprazolam and quinine metabolism is catalyzed by both CYP3A4 and CYP3A5. The present study showed that different KTZ enantiomers inhibit CYP3A4 and CYP3A5 to different degrees, indicating that structural differences among the enantiomers would be related to their inhibitory potency on these two enzymes.
Authors: M D Perloff; L L von Moltke; M H Court; T Kotegawa; R I Shader; D J Greenblatt Journal: J Pharmacol Exp Ther Date: 2000-02 Impact factor: 4.030
Authors: Rajaa A Mirghani; Jane Sayi; Eleni Aklillu; Annika Allqvist; Mary Jande; Agneta Wennerholm; Jaran Eriksen; Virginie M M Herben; Barry C Jones; Lars L Gustafsson; Leif Bertilsson Journal: Pharmacogenet Genomics Date: 2006-09 Impact factor: 2.089
Authors: David M Stresser; Marc I Broudy; Thuy Ho; Catherine E Cargill; Andrew P Blanchard; Raman Sharma; Andre A Dandeneau; Joseph J Goodwin; Stephanie D Turner; John C L Erve; Christopher J Patten; Shangara S Dehal; Charles L Crespi Journal: Drug Metab Dispos Date: 2004-01 Impact factor: 3.922
Authors: Nina Zemanova; Pavel Anzenbacher; Eva Anzenbacherova Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Date: 2022-04-12 Impact factor: 1.245
Authors: Aneta Novotná; Kristýna Krasulová; Iveta Bartoňková; Martina Korhoňová; Petr Bachleda; Pavel Anzenbacher; Zdeněk Dvořák Journal: PLoS One Date: 2014-10-24 Impact factor: 3.240
Authors: Takao Yamazaki; Amit Desai; David Han; Kota Kato; Donna Kowalski; Shahzad Akhtar; Christopher Lademacher; Laura Kovanda; Robert Townsend Journal: Clin Pharmacol Drug Dev Date: 2016-07-20
Authors: Aneta Novotna; Martina Korhonova; Iveta Bartonkova; Anatoly A Soshilov; Michael S Denison; Katerina Bogdanova; Milan Kolar; Petr Bednar; Zdenek Dvorak Journal: PLoS One Date: 2014-07-07 Impact factor: 3.240